Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

cancer vaccine | Image credit: IO Biotech
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3rd 2025

Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

March 31st 2025

Travis Osterman, DO, MS, FAMIA, FASCO
Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

October 25th 2024

More News

Immunotherapy word cloud: © ibreakstock - stock.adobe.com
April 15th 2023

Rural, Small Practices Slower to Adopt Immunotherapies

Gianna Melillo
Immunotherapies are an important breakthrough in cancer treatment, but little is known about which practices adopt the therapy or the pace at which they do so.
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist
April 13th 2023

Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist

Rose McNulty
Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.
Early Recognition Key to Management of Immunotherapy Toxicities
April 11th 2023

Early Recognition Key to Management of Immunotherapy Toxicities

Mary Caffrey
As much as immuno-oncology has been a leap forward, the ability to address immune-related adverse events is critical to making these therapies available in settings beyond academic centers; thus, the National Comprehensive Cancer Network offers clinical guidelines for management of toxicities.
Blood testing
April 8th 2023

DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes

Rose McNulty
A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.
FDA logo
April 5th 2023

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Kristi Rosa
The FDA has granted accelerated approval to enfortumab vedotin-ejfv plus pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
Jeremy Graff, Chief Scientific Officer, IMV
March 26th 2023

Delivery Matters: In Early Studies, DPX Technology Allows Vaccines to Persist When Cancer Pushes Back

Mary Caffrey
Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.
Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL
March 21st 2023

Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL

Rose McNulty
A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).
Needle and vaccine
March 16th 2023

Study Shows Immune Response After COVID-19 Vaccine in Majority of Patients Treated With CAR T-Cell Therapy

Rose McNulty
The majority of CAR T-cell therapy recipients developed a humoral immune response to vaccination against SARS-CoV-2 in a recent study, with a more robust vaccine schedule linked to higher antibody titers.
Logo for What We're Reading
March 15th 2023

What We’re Reading: Biomarker Testing in Kentucky; Opioid Guidelines Updated; EPA Limits in Drinking Water

AJMC Staff
Kentucky passes a bill to require insurers to cover biomarker tests for patients with cancer; CDC opioid guidelines updated in November may be too late for patients with chronic pain; the Environmental Protection Agency is proposing new limits to reduce dangerous human-manufactured chemicals in drinking water.
Kidneys
March 8th 2023

Lenvatinib Plus Pembrolizumab Shows Durable Efficacy Benefits vs Sunitinib in Renal Cell Carcinoma

Rose McNulty
The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.
Sashi Naidu, MD, Carolina Blood and Cancer Care Associates
March 6th 2023

Dr Sashi Naidu: Partnering With Molecular Diagnostic Labs Facilitates Advanced Cancer Care

Maggie L. Shaw
Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.
Skin cancer
March 1st 2023

Neoadjuvant Initiation of Pembrolizumab Improves Outcomes vs Adjuvant Therapy Alone in Advanced Melanoma

Rose McNulty
Starting immunotherapy prior to surgical resection led to better outcomes vs standard, adjuvant-only immunotherapy in a phase 2 trial of patients with advanced melanoma.
With Broad Input, Clinical Pathways Making a Difference for End Users
February 23rd 2023

With Broad Input, Clinical Pathways Making a Difference for End Users

Mary Caffrey
Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion
February 23rd 2023

Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion

Mary Caffrey
Breast cancer
February 22nd 2023

Oncolytic Virus Therapy Shows Promising Results in Early-Stage TNBC

Rose McNulty
Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).
Andrew Hertler, MD, FACP
February 20th 2023

New Century Health’s Andrew Hertler, MD, FACP: “You Have to Be Careful When You Look at Total Cost of Care”

Interview by Mary Caffrey
CAR T cells
February 18th 2023

Study Suggests Second-line Axi-Cel Is Cost-effective vs Standard Care in R/R DLBCL

Rose McNulty
Despite coming at a high cost, an analysis found that in some cases, chimeric antigen receptor T-cell therapy may be cost-effective compared with the standard of care in the second line or later for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Kidneys
February 16th 2023

After More Than 3 Years, Nivolumab With Cabozantinib Shows Sustained Response Over Sunitinib in RCC

Mary Caffrey
Long-term results show sustained benefit from the immunotherapy-TKI combination for patients with metastatic renal cell carcinoma regardless of risk profile or PD-L1 status.
Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years
February 9th 2023

Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years

Allison Inserro
Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results.
Esophageal cancer
February 7th 2023

Zanidatamab, With Biparatopic Binding to HER2, Shows 84% OS in Phase 2 Study of Gastroesophageal Adenocarcinoma

Mary Caffrey
The investigational therapy promises a new way to target HER2 while still using chemotherapy combinations.
Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL
February 4th 2023

Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL

Hayden E. Klein Rose McNulty
Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.
Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma
February 3rd 2023

Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma

Rose McNulty
The study suggests there is measurable amount of microbiome within the soft tissue sarcoma tumor environment, which was previously thought to be sterile.
'Persistent' Subset of Tumor Mutations May Predict Immunotherapy Response
January 26th 2023

"Persistent" Subset of Tumor Mutations May Predict Immunotherapy Response

Rose McNulty
A study published in Nature Medicine found that certain tumor mutations are more persistent and may predict immunotherapy responses more reliably than overall tumor mutational burden.
Lymphoma cell
January 19th 2023

Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL

Rose McNulty
A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.
Dr Alonso V. Pacheco
January 17th 2023

There Is a Need to Identify Patients Most Likely to Benefit From Immunotherapies, Says Dr Alonso V. Pacheco

Laura Joszt, MA Justina Petrullo
New immunotherapies are changing the shape of oncology care, but there is also a need for a system that provides these high-quality therapies to the patients most likely to benefit from them. This might mean doing an assessment and a deeper dive into patient functional status, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
image of science
January 14th 2023

From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH

Mary Caffrey
At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.
Image of a brain
January 10th 2023

Immune Profiling Study Offers Potential New Patient-Stratification Tools in Glioblastoma

Jared Kaltwasser
The findings include the identification of a 12-gene signature that could be used to categorize patients as high or low risk.
image of chimeric antigen receptor (CAR) T-cell
January 7th 2023

How CAR T Therapies Stack Up Against Standard of Care for LBCL Across Lines of Treatment, Cost Perspectives

Christina Mattina
During 2022, the FDA approved 2 chimeric antigen receptor (CAR) T-cell therapies for use in second-line treatment, offering new treatment choices but raising the question: What options remain once a patient relapses after CAR T?
research shows Disparate CAR T-Cell Therapy Access and Outcomes in MM, DLBCL
January 7th 2023

ASH Abstracts Reveal Disparate CAR T-Cell Therapy Access and Outcomes in MM, DLBCL

Christina Mattina
Access to and outcomes of chimeric antigen receptor (CAR) T-cell therapies may differ by characteristics such as race, ethnicity, gender, and geographic location among patients with cancer.
the top 5 IVBM coverage of 2022
December 27th 2022

Top Institute for Value-Based Medicine® Content in 2022

Hayden E. Klein
Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.
<12345678
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo